4 November 2026 ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026
3 November 2026 Oryzon announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
15 October 2026 ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant
28 September 2026 ORYZON receives European Medicines Agency approval to initiate the HOPE-2 Phase II study of vafidemstat for the treatment of Phelan-McDermid Syndrome (PMS)
31 August 2026 ORYZON announces Notice of Allowance for U.S. patent application covering iadademstat combination with gilteritinib
27 July 2026 ORYZON reports financial results and corporate update for half year ended June 30th, 2026
8 July 2026 ORYZON announces U.S. patent grant for vafidemstat in borderline personality disorder (BPD)
1 July 2026 ORYZON raises €12 million and signs a financing agreement with COFIDES to strengthen its balance sheet and accelerate its clinical programs